AUTHORS
Uma Borate, MBBS, MSc, Christopher Walker, PhD2, Ethan Hamp3, Adam Albitar, MD4, Jill Buss, PhD5, Ying Huang, MA, MS6, Tara L. Lin, MD7, Shivani Handa, MD8, Ronan Swords, MD9, Curtis Lachowiez, MD10, Elie Traer, MD, PhD11, Wendy Stock, MD12, Olatoyosi Odenike Jr, MD13, Anand Ashwin Patel, MD14, Maria R. Baer, MD15, Vu Duong, MD16, Eytan M Stein I, MD17, William Blum, MD18, Colin Vale19, Emily Curran, MD20, Yazan F. Madanat, MD21, Rebecca L Olin, MD22, Gary J. Schiller, MD23, Angela Nichols, NP24, Lacey Williams, MD25, Nyla Heerema, MD26, Timothy Chen, PhD27, Sonja Marcus, MPH28, Molly Martycz29, Mona Stefanos, MD, MBChB30, John Byrd, MD31, Brian Druker, MD32, Ross L. Levine, Prof. Dr.33, Ashley Yocum, PhD34, Joshua F. Zeidner, MD35, Alice Scott Mims, MD36, Maher Albitar, M.D.37, Ann-Kathrin Eisfeld, MD38
AFFILIATIONS
1 The Ohio State University, Columbus, Ohio, United States
2 The Ohio State University, Columbus, Ohio, United States
3 The Ohio State University, Columbus, Ohio, United States
4 Genomic Testing Cooperative, Lake Forest, California, United States
5 The Ohio State University, Columbus, Ohio, United States
6 The Ohio State University, Columbus, Ohio, United States
7 University of Kansas Medical Center, Kansas City, Kansas, United States
8 The Ohio State University, Columbus, Ohio, United States
9 Oregon Health & Science University, Portland, Oregon, United States
10 Oregon Health & Science University, Portland, Oregon, United States
11 Oregon Health & Science University, Portland, Oregon, United States
12 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
13 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
14 University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
15 University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
16 University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
17 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
18 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
19 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
20 University of Cincinnati, Cincinnati, Ohio, United States
21 University of Texas Southwestern Medical Center, Dallas, Texas, United States
22 University of California San Francisco, San Francisco, California, United States
23 David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California, United States
24 University of North Carolina, Chapel Hill, North Carolina, United States
25 University of North Carolina, Chapel Hill, North Carolina, United States
26 The Ohio State University, Columbus, Ohio, United States
27 The Ohio State University, Columbus, Ohio, United States
28 Blood Cancer United, Washington, District of Columbia, United States
29 The Ohio State University, Columbus, Ohio, United States
30 The Ohio State University, Columbus, Ohio, United States
31 University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
32 Oregon Health & Science University, Portland, Oregon, United States
33 Memorial Sloan Kettering Cancer Center, New York City, New York, United States
34 Blood Cancer United, Washington, District of Columbia, United States
35 University of North Carolina, Chapel Hill, North Carolina, United States
36 The Ohio State University, Columbus, Ohio, United States
37 Genomic Testing Cooperative, Lake Forest, California, United States
38 The Ohio State University, Columbus, Ohio, United States
ABSTRACT
Background: OPTI-AML (NCT03013998) is a prospective randomized phase 2 trial comparing azacytidine plus venetoclax for 28D (AV28) versus 14D (AV14), with a primary endpoint of complete remission rate by cycle (C) two in patients (pts) ≥60 years with newly diagnosed acute myeloid leukemia (AML) AV14 was not non-inferior to AV28 (Borate et al., Blood 2026). Gene mutation data from local testing suggested possible genotype dependence for treatment intensity, however, refined dynamic molecular profiling to delineate treatment response represent an unmatched opportunity.
Methods: Ultra-sensitive sequencing was performed for 160 pts with paired samples on C1D1 and C1D21, including separate white blood cell (WBC) and cell-free (cf)DNA, using a CLIA-approved panel of ~300 genes with a sensitivity to variant allele fraction (VAF) of 0.001 (Genomic Testing Cooperative). Tumor load, measured in mutant DNA molecules per mL of plasma, and its dynamics were assessed using combined cellular/cell-free analyses. Mutation persistence was defined as C1D21 VAF ≥2%. Arm-stratified univariable Cox models evaluated overall survival (OS) and progression-free survival (PFS).
Results: Molecular profiling was significantly enhanced by centralized high-sensitivity analyses of WBCs, with 30 additional variants in previously tested, risk-group informing genes. These newly uncovered mutation samples changed the ELN2024 risk group assignment of 15 of 158 evaluable pts.
To investigate whether specific molecular subgroups derived a dose-dependent benefit, we assessed the correlation between response and mutation status of commonly mutated genes in AML. Pts harboring mutations in RUNX1 (AV28, n=20; AV14, n=23) or TET2 (AV28, n=16; AV14, n=15) had higher likelihood of CR achievement with AV28 compared to AV14 (RUNX1, OR 0.2 [0.06-0.58], TET2, OR 0.21 [0.04-0.75]), while the presence of SRSF2 mutations (AV28, n=19; AV14, n=10) favored AV14 (OR 0.24 [0.07-0.73]), suggesting mutation-specific sensitivity to venetoclax. TP53-mutated patients had similar outcomes with AV14 versus AV28, highlighting that this subset may be spared unnecessary toxicities with AV28. Importantly, none of the current treatment response-defining mutations (ELN 2024) impacted on AV14 versus AV28.
While MRD determination was based on immunophenotyping in the clinical trial setting, we next assessed refinement using molecular MRD. Here, we distinguished between known clonal hematopoiesis genes versus AML driver mutations (RAS genes, FLT3, NPM1, WT1, and TP53 [included as a driver gene]). Among the 149 pts with paired WBC samples at diagnosis and C1D21, for those who were molecular MRD+ (AV28, n=15; AV14, n=19), AV14 was associated with inferior OS (hazard ratio [HR], 2.65; 95% CI, 1.13–6.19) and PFS (HR, 2.76; 95% CI, 1.13–6.71). In contrast, among pts who were molecular MRD- (AV28, n=58; AV14, n=57), outcomes were comparable between AV14 and AV28 for OS (HR, 1.36; 95% CI, 0.70–2.64). This suggests that patients who achieve molecular MRD negativity might be able to be de-escalated to AV14 after C1.
Lastly, we assessed the utility of paired cfDNA testing for evaluation of tumor load. Excitingly, after cohort separation into training and testing sets, a random forest model incorporating the molecular tumor load at diagnosis along with other molecular and demographic features (TP53 mutation status, cytogenetics, and patient age) was able to predict achievement of CR with AV14 (sensitivity: 98.8%, specificity: 100%), indicating the importance of tumor burden for treatment intensity/AV duration. Interestingly, changes in tumor load between C1D1 and C1D21 were not associated with response, indicating that only baseline levels of tumor load predicted CR, reflecting inadequate changes in tumor load by AV14 therapy. In general, cfDNA served as an equivalent, if not superior, less invasive molecular monitoring tool that captured cellular-based molecular results for AML patients.
Conclusions: Centralized, sensitive molecular profiling allowed for reclassification of specific mutations at diagnosis can help to select AV14 vs AV28 for individual pts. Moreover, molecular MRD assessment and use of molecular tumor load including both cellular and cell-free analyses can further refine longitudinal treatment guidance and opportunities for treatment de-intensification. This analysis sets precedence for refined molecular monitoring and dynamic treatment adjustments for leukemia patients.
DISCLOSURES
Ann-Kathrin Eisfeld, MD: Servier - Consultancy (Includes expert testimony)